Back to News
Market Impact: 0.15
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Source: Business Wire
Artificial IntelligenceTechnology & InnovationHealthcare & BiotechCompany Fundamentals
Lōkahi Therapeutics announced that its proprietary ai² PIPELINE process is advancing from an internal asset-development engine into a revenue-generating platform. The release signals a potential expansion of the company's business model through commercialization of its AI-enabled drug-development capabilities, though no financial metrics, customer contracts, or revenue targets were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Cathie Wood 'always feels better when the market is worried' — here's why
- These funds tout hefty income tied to the tech trade – if you’re willing to deal with the complexity
- Street Calls of The Week
- AI stock selloff drives investors to China, India, and overlooked Asian sectors
- Asia Markets Brace for More AI Volatility